Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis - Wikidata - thesis-toulmin - TriplyDB

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

http://www.wikidata.org/entity/Q24676203

about

PHLPP-mediated dephosphorylation of S6K1 inhibits protein translation and cell growth Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1 The TOR pathway comes of age Mammalian target of rapamycin: a central node of complex signaling cascades mTOR inhibitors in advanced renal cell carcinoma Aging as an event of proteostasis collapse The TSC1-TSC2 complex: a molecular switchboard controlling cell growth A complex interplay between Akt, TSC2 and the two mTOR complexes mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis The Emerging Role of Branched-Chain Amino Acids in Insulin Resistance and Metabolism What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway Turning off AKT: PHLPP as a drug target The proteomic landscape of triple-negative breast cancer.Genomic analysis of the function of the transcription factor gata3 during development of the mammalian inner ear Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR Structural Basis of Human p70 Ribosomal S6 Kinase-1 Regulation by Activation Loop Phosphorylation An ATP-site on-off switch that restricts phosphatase accessibility of Akt Maximising the potential of AKT inhibitors as anti-cancer treatments Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy Poly(ester amine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung tumorigenesis Overexpression of Akt1 enhances adipogenesis and leads to lipoma formation in zebrafish Phosphorylation of IRS1 at serine 307 in response to insulin in human adipocytes is not likely to be catalyzed by p70 ribosomal S6 kinase PAS kinase is required for normal cellular energy balance Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2 Hyperinsulinemia: effect on cardiac mass/function, angiotensin II receptor expression, and insulin signaling pathways Tuberous sclerosis complex 2 (TSC2) regulates cell migration and polarity through activation of CDC42 and RAC1 Experimental Evolution Reveals Interplay between Sch9 and Polyploid Stability in Yeast The E3 ubiquitin ligase ZNRF2 is a substrate of mTORC1 and regulates its activation by amino acids The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Lifespan extension by conditions that inhibit translation in Caenorhabditis elegans mTOR signaling at a glance Insulin is a stronger inducer of insulin resistance than hyperglycemia in mice with type 1 diabetes mellitus (T1DM).Increased basal level of Akt-dependent insulin signaling may be responsible for the development of insulin resistance High-fat-diet-induced obesity and heart dysfunction are regulated by the TOR pathway in Drosophila Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production.Stromelysin-3 over-expression enhances tumourigenesis in MCF-7 and MDA-MB-231 breast cancer cell lines: involvement of the IGF-1 signalling pathway.PDK2: the missing piece in the receptor tyrosine kinase signaling pathway puzzle.

P2860

Q24292938-BB1CBB28-2C00-45F5-A694-807373A34D81 Q24306330-75A37215-84ED-4030-94AB-1608CFEEB15D Q24319851-CCAA29D3-61F5-4511-8B01-665769C0327F Q24568353-485EC42C-D35D-43A0-8C97-5952F1215658 Q24601702-5DB30759-14BB-4620-A37D-E8F3C1E127CC Q24612127-8DBCB7CE-3C88-4FE6-8215-11CE6D61DA5B Q24630961-39FB9C31-FBCF-4FAF-9544-4D7090016C03 Q24645204-3E8AEE7C-5292-40CA-9F08-3D4BD575D6B8 Q24655791-E8FF771F-8E22-4053-B624-3E6268A67507 Q24658113-EA1279C9-F2B3-4F02-8C54-CDAE08BFF736 Q24670558-4C22D108-B772-4B71-845C-1423284FB660 Q26744725-39DDB13B-51D0-48E5-8285-95471FBD6C4A Q26825780-CA407DCD-A12E-4FB3-B862-148F3BB27AE4 Q27014094-36CA1E41-F412-4A72-9498-15EEBADC2A84 Q27320721-430F1CA3-284F-4AD3-A002-73BE8F51726A Q27341203-C86DAED7-34E5-4032-AD98-78536D78A25D Q27647018-72FA3E01-4FFA-4355-9F52-3E7C02E24223 Q27658004-731EE2A6-57ED-4ECC-B59D-2C483BDFED1D Q27678970-8E21AB81-3AD1-44AC-927D-9481125F0501 Q28072254-C3846AF6-766B-4553-A505-0E1B93E6157D Q28079861-9E848A8A-F1CF-423B-A09E-679B48346744 Q28384723-272DBB6E-CAD1-4BDD-9948-BBA2CBEDD630 Q28483822-E7DC33F1-B739-46B3-A245-EDCB88A2C0CF Q28485906-8E3C6E73-F1DA-4665-A65E-EE2AEC259498 Q28506039-BF7B585B-5FF6-44DA-A8F1-E890A1E1A336 Q28509303-EAA87094-C450-40AE-B67F-C0D1ADA84B5C Q28565051-1C472DBC-716D-4482-A694-1E0028DAC80B Q28565798-70309D7E-7EA7-4A0A-8FDD-12693F7D08DC Q28822236-AB814847-A27B-4B6C-BA82-539E6BC01BA5 Q28829525-80D704CD-A384-4C90-A18F-24CE0B99B779 Q29547302-A39B000B-075D-4CF1-9239-935B2809ACED Q29547767-22CEABF6-FCD9-4C39-965A-C0314245D876 Q29616003-04ECE628-58F3-47A7-BDC4-E03A210639F9 Q29619857-CEF59E66-793A-4B9C-9E65-F29A499DD86A Q30434577-7C25EDE1-256F-46A5-A986-641BAA3BB679 Q30434586-4183B6A0-DB59-4982-9177-A27B4A9260FE Q30497986-71EE59DF-7F4B-4A9F-940C-96DB0F6DA020 Q30498613-272C35F2-F258-462D-B110-8CB1E0427B84 Q33269607-B90E279D-09E4-4343-A1DD-55F065281890 Q33341346-D612BCE5-F584-4BBF-991A-56B33E7230E3

P2860

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

http://www.wikidata.org/entity/Q24676203

description

2004 nî lūn-bûn

@nan

2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

@ast

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

@en

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

@nl

type

label

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

@ast

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

@en

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

@nl

prefLabel

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

@ast

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

@en

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

@nl

P1433

Q24676203-BBBC7535-72F1-420D-8F5F-883149B05DED

P1476

Q24676203-4D636F41-1AA5-4C36-B2F0-17024476D61E

P2093

Q24676203-3E680026-5AA3-4583-BC79-273D93F643B4

P2860

Q24676203-03237CFE-68EB-4C01-81B7-6E40D38C764D

Q24676203-038A5345-9550-4A09-9EB0-F523B195B28D

Q24676203-08651DB2-21BB-47F8-8F0F-150E77692EE5

Q24676203-10B7A27A-2D45-4F85-8E7C-AC109611326A

Q24676203-1C287453-82FA-4CDB-974C-537DD75DD96D

Q24676203-207D5CA8-3702-41C5-BF6A-CD6326319399

Q24676203-22C46F56-9851-459C-B37A-E86103229C23

Q24676203-28B53AEC-3C32-4C0D-B9E5-85E4539BB34E

Q24676203-3F8850C7-3CFB-41DB-ADF4-81B93E0A3F4B

Q24676203-4A7FE58C-9998-4BE6-8ADE-27B7B41ED7D8

P304

Q24676203-397877E1-D3AC-42DD-8E3C-BD3F1246E8E7

P31

Q24676203-1B3AD163-D903-4596-963F-B6C1204001BD

Q24676203-9855FF55-EFF3-4042-81C5-BD5EAE8869F4

P3181

Q24676203-BC1BE131-4E08-4A17-9EA3-A8E9B190B9B4

P356

Q24676203-F67E0510-7C4B-43C9-8008-1A1CB24F8BF7

P407

Q24676203-0CAD8898-E867-46CA-AAB0-C30B33F677E5

P433

Q24676203-E3751E3F-5096-42A0-A2B4-DF89773C158B

P478

Q24676203-5180F0B0-8926-4769-B9B9-A54067347442

P577

Q24676203-09D0BBCE-CE80-4C20-B838-92F9225A5808

P5875

Q24676203-BD29FF65-6052-453D-82DA-08E0D1D2053C

P698

Q24676203-BF532114-BF89-4920-AA7F-DEAD40AF33E5

P921

Q24676203-3CEB6E8F-909B-43B8-B40C-0FD5F7901756

Q24676203-3DC82CE2-265F-45F6-9D38-2CAE44EE3FCF

Q24676203-41FE0932-B7AE-4DCF-AA24-0541974B86E9

Q24676203-837E1B17-9399-4C1C-9E94-625B153711A5

Q24676203-8D0F1F51-F0A6-4F49-BE82-FCBFEDBEDDB8

Q24676203-C29F1F82-56A6-46E8-8088-D28885DE5944

P932

Q24676203-A659A37E-0904-4C15-B97F-C28C4C49F129

P3181

P356

P1433

Journal of Cell Biology

P1476

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

@en

P2093

Brendan D Manning

http://www.w3.org/2001/XMLSchema#string

P2860

Insulin signalling and the regulation of glucose and lipid metabolism

Modulation of human insulin receptor substrate-1 tyrosine phosphorylation by protein kinase Cdelta

Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

TSC2 mediates cellular energy response to control cell growth and survival

TOR, a central controller of cell growth.

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307)

A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells

Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors

P304

399-403

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1843251

http://www.w3.org/2001/XMLSchema#string

P356

10.1083/JCB.200408161

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

167

http://www.w3.org/2001/XMLSchema#string

P577

2004-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8186917

http://www.w3.org/2001/XMLSchema#string

P698

15533996

http://www.w3.org/2001/XMLSchema#string

P921

proto-oncogene proteins

physiological phenomena

neoplasm proteins

P932

2172491

http://www.w3.org/2001/XMLSchema#string